Open Access

L-Carnitine supplementation reduces the general fatigue of cancer patients during chemotherapy

  • Authors:
    • Hiroki Matsui
    • Takahiro Einama
    • Shunsuke Shichi
    • Ryo Kanazawa
    • Kazuaki Shibuya
    • Takashi Suzuki
    • Fumihiko Matsuzawa
    • Taku Hashimoto
    • Shigenori Homma
    • Junji Yamamoto
    • Akinobu Taketomi
    • Hironori Abe
  • View Affiliations

  • Published online on: January 16, 2018     https://doi.org/10.3892/mco.2018.1557
  • Pages: 413-416
  • Copyright: © Matsui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

L-Carnitine (LC) plays an important role in the metabolism of fatty acids, and LC deficiency is associated with a feeling of weakness or general fatigue. Cancer patients receiving chemotherapy often develop LC deficiency, which is considered to be a factor contributing to general fatigue. The aim of the present study was to evaluate the efficacy of LC supplementation as a treatment for general fatigue in cancer patients during chemotherapy. A total of 11 cancer patients who were suffering from general fatigue during chemotherapy in our hospital between September 2014 and December 2015 were examined (6 cases involved adjuvant chemotherapy and 5 cases involved chemotherapy for unresectable or recurrent disease). The patients were administered 1,500 mg/day of levocarnitine per os, and the change in mean daily fatigue from the baseline to 8 weeks was assessed using the Brief Fatigue Inventory. The change in the plasma levels of albumin and the lymphocyte counts from the baseline to 8 weeks were also assessed. LC supplementation reduced general fatigue in all cases. Moreover, LC supplementation maintained the plasma levels of albumin and lymphocyte counts during chemotherapy, and enabled patients to continue chemotherapy sequentially without dose reduction. Therefore, LC supplementation improved general fatigue in all the examined cancer patients during chemotherapy. This treatment may make improve the tolerability of chemotherapy in cancer patients by reducing general fatigue and improving the nutritional status.

References

1 

Mock V, Atkinson A, Barsevick AM, Berger AM, Cimprich B, Eisenberger MA, Hinds P, Kaldor P, Otis-Green SA and Piper BF: Cancer-related fatigue. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 5:1054–1078. 2007. View Article : Google Scholar : PubMed/NCBI

2 

Glaspy J: Anemia and fatigue in cancer patients. Cancer. 92 Suppl 6:S1719–S1724. 2001. View Article : Google Scholar

3 

Foster DW: The role of the carnitine system in human metabolism. Ann N Y Acad Sci. 1033:1–16. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, Fleishman S, Lapin J, Klein E, Lesage P, et al: L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: A preliminary analysis. Ann N Y Acad Sci. 1033:168–176. 2004. View Article : Google Scholar : PubMed/NCBI

5 

Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, Ferraro B, Canestrari F, Baldelli AM, De Gaetano A, et al: Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer. 86:1854–1857. 2002. View Article : Google Scholar : PubMed/NCBI

6 

Waldner R, Laschan C, Lohninger A, Gessner M, Tüchler H, Huemer M, Spiegel W and Karlic H: Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res Clin Oncol. 132:121–128. 2006. View Article : Google Scholar : PubMed/NCBI

7 

Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C and Gianni L: Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 41:1746–1750. 2005. View Article : Google Scholar : PubMed/NCBI

8 

Hockenberry MJ, Hooke MC, Gregurich M and McCarthy K: Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol. 31:664–669. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessì M, Spiga C, Astara G, et al: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22:136–145. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK and Huber SL: The rapid assessment of fatigue severity in cancer patients: Use of the brief fatigue inventory. Cancer. 85:1186–1196. 1999. View Article : Google Scholar : PubMed/NCBI

11 

Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS and Uchitomi Y: Validation study of the Japanese version of the brief fatigue inventory. J Pain Symptom Manage. 25:106–117. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Dodson WL, Sachan DS, Krauss S and Hanna W: Alterations of serum and urinary carnitine profiles in cancer patients: Hypothesis of possible significance. J Am Coll Nutr. 8:133–142. 1989. View Article : Google Scholar : PubMed/NCBI

13 

Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A and Calvani M: Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol. 182:339–350. 2000. View Article : Google Scholar : PubMed/NCBI

14 

Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM and Amato A; CHIEF Investigators, : Intravenous L-carnitine increases plasma carnitine, reduces fatigue and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis. 37:1018–1028. 2001. View Article : Google Scholar : PubMed/NCBI

15 

McNeil C: Cancer fatigue: One drug fails but more are in the pipeline. J Natl Cancer Inst. 93:892–893. 2001. View Article : Google Scholar : PubMed/NCBI

16 

Ringseis R, Keller J and Eder K: Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: Evidence from experimental and clinical studies. Eur J Nutr. 52:1421–1442. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Fatouros IG, Douroudos I, Panagoutsos S, Pasadakis P, Nikolaidis MG, Chatzinikolaou A, Sovatzidis A, Michailidis Y, Jamurtas AZ, Mandalidis D, et al: Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc. 42:1809–1818. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J, Portenoy RK and Esteban-Cruciani N: L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: A double-blind, placebo-controlled study. J Pain Symptom Manage. 37:622–631. 2009. View Article : Google Scholar : PubMed/NCBI

19 

Iwase S, Kawaguchi T, Yotsumoto D, Doi T, Miyara K, Odagiri H, Kitamura K, Ariyoshi K, Miyaji T, Ishiki H, et al: Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: A multi-institutional, randomized, exploratory trial (JORTC-CAM01). Support Care Cancer. 24:637–646. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Malaguarnera M, Li Volti G and Galvano F: Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: A randomized, double-blind, placebo-controlled study. Am J Clin Nutr. 93:799–808. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Cruciani RA, Zhang JJ, Manola J, Cella D, Ansari B and Fisch MJ: L-carnitine supplementation for the management of fatigue in patients with cancer: An eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 30:3864–3869. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March 2018
Volume 8 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Matsui, H., Einama, T., Shichi, S., Kanazawa, R., Shibuya, K., Suzuki, T. ... Abe, H. (2018). L-Carnitine supplementation reduces the general fatigue of cancer patients during chemotherapy. Molecular and Clinical Oncology, 8, 413-416. https://doi.org/10.3892/mco.2018.1557
MLA
Matsui, H., Einama, T., Shichi, S., Kanazawa, R., Shibuya, K., Suzuki, T., Matsuzawa, F., Hashimoto, T., Homma, S., Yamamoto, J., Taketomi, A., Abe, H."L-Carnitine supplementation reduces the general fatigue of cancer patients during chemotherapy". Molecular and Clinical Oncology 8.3 (2018): 413-416.
Chicago
Matsui, H., Einama, T., Shichi, S., Kanazawa, R., Shibuya, K., Suzuki, T., Matsuzawa, F., Hashimoto, T., Homma, S., Yamamoto, J., Taketomi, A., Abe, H."L-Carnitine supplementation reduces the general fatigue of cancer patients during chemotherapy". Molecular and Clinical Oncology 8, no. 3 (2018): 413-416. https://doi.org/10.3892/mco.2018.1557